Interview of Mario Caria by Hannah Kuchler from the Financial Times

Kuste Biopharma to participate at upcoming conferences

Kuste Biopharma

Develops therapies for unmet medical inflammatory urological diseases

Objective

Develops therapies for unmet medical inflammatory urological diseases such as Bladder Pain Syndrome/Interstitial Cystitis

Development

Two small peptides acting in the JNK inhibition, have reached up to Phase 3 results.

Press releases

Read more about KUSTE BIOPHARMA in the medias and check our press releases.

Proprietary molecules

10+ years extensively studied, proven safe and efficacious JNK inhibitors for a variety of therapeutic applications.

JNK INHIBITION

Inhibitors of the JNK pathway have a proven therapeutic impact in the treatment of inflammatory diseases.

Launching studies

Launching clinical studies for the unmet clinical need of BPS/IC and preclinical on other inflammatory pathologies e.g. IBD

Discover the team

Governance

Read more about our Scientific Advisory Board and Management Team…

Kuste Biopharma

129 rue Servient
69326 Lyon Cedex 3

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530
contact@kustebiopharma.com

Logo-kuste-Biopharma-Vertical-desktop
Retour haut de page